#404 ‒ Mental health beyond neurotransmitters: the role of hormones in psychiatry, why symptom reduction isn't enough, and the future of psychedelic therapies | Linus Abrams, M.D.
00:03:21Yeah. Yeah. I did a pivot after 30 years. I felt like I was in a bit of a rut. Like I was
00:03:32enjoying my practice, but I felt I wasn't learning as much as I wanted to learn.
00:03:40And there are a number of factors that we can talk about that drove me in this direction, but the pivot is quite recent and I'm learning about endocrinology as we speak. It's been a recently evolving trend, but I've thought about it deeply and I hope some of that comes across in the podcast today.
00:04:07So tell me what it was during the first 30 years of your practice that, A, that gave you satisfaction and that you loved, and, sorry, B, that you were beginning to fatigue of or question or feel was insufficient to help your patients.
00:04:26Sure. Well, I see myself basically as a kind of humanistic, existential-oriented psychiatrist who happens to be practicing psychopharmacology as a way to make a living and having an expertise in bipolar spectrum disorders.
00:04:45But I found that psychopharmacology was perceived ambivalently for the most part, even in very successful cases from an objective point of view in terms of symptom reduction.
00:09:40Yep. So yet, in other words, something you said a moment ago rings very important, which is,
00:09:46even though you've used the term psychopharmacologist several times already,
00:09:51implying that the tool, the main tool you use is a pharmacologic tool. The human story piece of it
00:09:59is the diagnosis, right? I mean, presumably part of the diagnosis is ratified through
00:10:04a hypothesis of, hey, I think if I'm right on the diagnosis, this medication should make things a
00:10:10little bit better. But you have to have a very good hypothesis based on your subjective interaction
00:10:15with that patient. Yes and no. Yes and no. On both counts. First of all, I do a lot of psychotherapy
00:10:22too, because I'm one of those rare people, not in a special way, but in a self-directed way,
00:10:32who chose a residency program at Harvard that trained both psychotherapy and psychopharmacology.
00:10:39And I did that quite intentionally because I wanted to have a lot of cases where I was doing both as opposed to dividing and partitioning a patient's care because that led to my curiosity and the psychotherapeutic aspect of it.
00:10:59Yeah. Do you think that that's – I know from other friends who have done psychiatry residencies at Harvard that, at least according to them, and I'm asking you for that to clarify, is Harvard unique in that, in that it still preserves that legacy of –
00:11:17Harvard is a very heterogeneous institution, and it really depends on which area of which
00:11:28particular hospital, which training program, because there are a number of different training
00:20:23It's a drug that a lot of non-psychiatrists are very comfortable prescribing, which I
00:20:28thing speaks to its relative safety and ease of use. It's a drug that, as far as I can tell,
00:20:34really is administered at only two doses typically, 10 and 20 milligrams. Although I guess you could
00:20:39cut the 10 in half and start at five, but those seem to be the two doses. The other thing I've
00:20:43noticed is it seems to be a drug that's often prescribed not for depression, but rather for
00:20:50almost like rumination or... OCD? Yeah. Yeah. A little bit of OCD. That's an anxiety disorder.
00:21:00Yes. So you're saying it's more in the anxiety cluster than depressive?
00:21:03No. No. It works for both. So it was developed really for what we now call dysthymic disorder,
00:21:10which is different. Which really I do think of as depressive. I mean, dysthymia and anhedonia
00:21:14seem to be really core parts of depression, right? They're different though. Yes.
00:21:19Dysthymia is a chronic low-grade depressive tendency, as opposed to a major depressive
00:21:29episode. So major depression has a bigger amplitude, but typically a lower frequency.
00:21:38Dysthymia is a chronic tendency, if you were to draw a graph of it, where the mood would be below
00:21:45the baseline to a degree that takes a toll on the quality of life of the person who has it.
00:21:52And the goal of the medication is to elevate that toward the mean.
00:21:59And it's interesting that something as describable as dysthymia responds to purely more serotonin
00:22:09without necessarily more, and if anything, less dopamine and norepinephrine if presumably
00:22:15there's a compensation and they go down? Not necessarily, but the side effect profile
00:22:20tends to be better. So remember, when fluoxetine came out, the first SSRI, really the first of
00:22:28the next generation of anti-anxiety, antidepressants, to call them dual intended
00:22:37targets. So it isn't that SSRIs are unique in helping dysthymia, but when they were invented,
00:22:49the existing medications on the market, the tricyclic antidepressants, had typically much
00:22:57more severe side effects, much more severe, and were dangerous in overdose. So they were potentially
00:23:03lethal in overdose. And they had side effects like anticholinergic side effects, but to a
00:23:11severe degree that affected, that gave people terrible constipation, dry mouth, orthostatic
00:23:19hypotension, a host of symptoms that was problematic. And so that class was problematic.
00:23:27like MAO inhibitors, another potentially dangerous drug, if combined with a food containing
00:23:35tyramine, the so-called like the cheese reaction. So people had to be on diets,
00:23:43monitoring their intake of tyramine-containing foods. And it was very anxiety-provoking for
00:23:50those patients. Ironically, let's say someone with anxiety or panic disorder, who's taking
00:23:55medication that they know can give them a hypertensive crisis. So that was the backdrop
00:24:01from which SSRIs came. And SSRIs are really remarkably benign from a side effect profile
00:24:09compared to those older classes of drugs. And then the SNRIs, which I was starting to allude to,
00:24:17if you want me to pivot to that, they're balanced between serotonin and norepinephrine. And the
00:24:25major ones are venlafaxine and desvenlafaxine, Cymbalta and Pristique. Yeah. And those can be
00:24:37very effective and potentially less likely to cause the cognitive dulling or affective blunting
00:24:45that people sometimes get with SSRIs or the cognitive exacerbation, let's say, of an underlying
00:24:54subclinical or full-blown clinical diagnosis of ADHD.
00:25:01So when would an SNRI, which again, you always think the newer the drug, the better it is,
00:25:08but when would you turn to an SSRI over an SNRI?
00:25:14I would turn to an SSRI if I wanted to max out the serotonergic component.
00:25:21And, for example, OCD is a condition that responds better to aggressive serotonergic
00:25:30modulation, or I shouldn't use that word because later I'm going to use a different vocabulary to
00:25:38describe it, but signal amplification. You really want to turn up that serotonin signal
00:25:45with OCD, and also with PTSD. You want to turn it up. And these are generalizations.
00:25:54You know, every one is different. But as a generalization, I would say that's the case
00:26:00from my experience. So help me think about how you evaluate a patient that's coming to you
00:26:08for a given condition. And we can even just broadly pick several conditions. We could start
00:26:13with bipolar because that's obviously very complicated and it's something that I know
00:26:17you have a lot of experience with. So how often is it that a person is coming to you for the first
00:26:22presentation of bipolar disorder rather than someone who's coming to you because they've
00:26:28been recalcitrant to lots of therapy and they're sort of winding up seeing you as sort of a last
00:26:33resort hope? The interesting thing, Peter, if they're coming to me for bipolar, most of the
00:26:40time they don't know they have bipolar. Okay. So you're the one that's sort of
00:26:44creating the framework around this. Yeah. I'm the one who's throwing out that hypothesis.
00:26:51Okay. So tell me about what a person, again, it's hard to pick an average, but pick, you know,
00:26:59sort of use your experience. Well, let me put it a different way, if that's okay. Typically,
00:27:05unless I have a patient in crisis where I'm worried about their safety or self-harm or harm
00:27:12to others, someone who's in an extreme radical situation where I have to focus on safety and
00:27:20protection, I really don't approach a consultation that differently for all patients. It all starts
00:27:30with how can I be of help? What are you thinking about in terms of talking with me and trying to
00:27:39feel better? And that's always the starting point. And I let the patient lead me to the problem.
00:27:48So a person with undiagnosed bipolar will typically voice what concerns? Are they more
00:27:56troubled by the manic symptoms? Are they more troubled by the depressive symptoms?
00:28:00Well, in the population I see, they're more troubled by depression. And the type of bipolar
00:28:10we're alluding to is so-called bipolar 2. Bipolar, much more common form of it, where the manic part
00:28:21is not a true full-blown mania. It's so-called hypomania. And that can be very adaptive.
00:28:27As a matter of fact, I would say maybe over the course of my career, maybe a third
00:28:33of my patient population have been incredibly successful people who've used their hypomanic0.96
00:28:42drive to achieve remarkable things. And so it can be very adaptive.
00:28:48But when they get depressed, they respond differently to antidepressants than someone
00:28:56who has non-bipolar depression. So unipolar depression, which is non-bipolar depression,
00:29:04and bipolar depression have different pharmacologic response profiles.
00:29:12Can you say more about how they differ and what the implication is?
00:29:15Absolutely. Well, someone with unipolar depression will typically have a, if the trial succeeds, a favorable response. They'll feel better. Someone with bipolar depression could either have a negative response. It could trigger so-called mood cycling.
00:29:35They could become hypomanic in an unpleasant way, agitated, have trouble sleeping, have racing thoughts, a variety of symptoms, or they could have a mixed state, a combination of depression.
00:29:51That's very common. A combination of depressive symptoms, feeling sad, potentially hopeless,
00:30:01but also having feelings of agitation, physically feeling agitated and disconcerted.
00:30:10And you're saying that if you fail to make the diagnosis of unipolar versus bipolar,
00:30:17and you prescribe the same drug, and the first line might be an SSRI.
00:30:23Well, there are ways to circumvent that. If you ask the right questions,
00:30:29you're less likely to prescribe the wrong drug.
00:30:32And what would be the wrong drug for the bipolar that might be the right drug for the unipolar?
00:30:39Sure. The wrong drug would be, I would say, any antidepressant instead of a mood stabilizer.
00:30:47like lamotrigine. I see. Because lamotrigine, sorry to interrupt, lamotrigine can be very
00:30:54effective about treating depression. People think of bipolar drugs as treating the elevated moods,
00:31:03but lithium and lamotrigine, for example, can be very effective at treating depression with
00:31:12monotherapy for many patients. And that's lamictal, I assume?
00:32:08Exactly. And it has the ceiling effects for certain drugs and the floor effects. So it's less likely that adding an antidepressant will make them more depressed or hypomanic or put them into a mixed state.
00:32:25Now, in an individual who you do not believe has bipolar disorder, but still has irritability and mood swings, can SSRIs or SNRIs stabilize mood?
00:32:39Well, irritability is such a huge category.
00:32:45And a lot of people with depression have a lot of irritability.
00:32:51So irritability can be part of a classic dysthymic disorder presentation.
00:32:58Irritability, pessimism, sadness, a lack of optimism, a lack of planning forward.
00:33:12Those can all be part of dyslemic disorder.
00:33:16So irritability can exist in that context.
00:33:20In a bipolar context, it can be more dramatic.
00:39:47So that's what I'm sort of getting at, right, is do you believe that there is a much higher incidence of clinical depression today than there would have been 10,000 years ago?
00:39:59That's one of those questions I could speculate about.
00:40:03But, you know, Peter, when I look at our world today and our children and the kind of world they're facing, they're facing enormous challenges existentially.
00:40:27If our primary identity is our intellectual function and we're creating machines that are going to surpass our own intellectual function or in certain examples have surpassed it in certain areas, then how can I flourish?
00:40:49But let's go back in time 10 years when nobody was thinking about that other than a few people.
00:41:23in certain places in the cold. But again, when I think about those things,
00:41:28and I'm not disputing that those things are happening, but contrast that with how miserable
00:41:33it must have been. Just imagine what it was like to be alive 1,000 years ago. Wouldn't you rather
00:41:39be the least wealthy person in the United States today than the King of England 1,000 years ago?
00:41:47You know, it's very complicated. I'm just saying, for as lousy,
00:41:53and we can talk about all the things that make the world a lousy place today. It's still
00:41:57infinitely better than it was just a thousand years ago. From a bourgeois point of view,
00:42:02yes. But from a relational point of view- Well, so that's exactly where I'm trying to go with
00:42:08this, which is what are the factors? The word environmental trigger, I think, is preventing
00:42:16me from really getting at the question. Yeah, I think I was premature.
00:42:19Well, no, no, no. I'm just saying I'm genuinely curious as to what do we think is the causal relationship between mental health deteriorating and the world we inhabit?
00:42:34Well, I think a lot of it has to do with things that are spoken about, social media, people being on digital devices, being isolated, and having a distorted view of the world created by commerce to be kind of sucked into their algorithms.
00:43:04and therefore isolated as a result. And people are having less sex. People are having fewer
00:43:12romantic relationships. People are using online pornography more in the absence of
00:43:19relationships. Fertility rates are going down. Reproductive rates are going down.
00:43:26there's this great divide socioeconomically that i think is having an outsized role too
00:43:34so when the king was the king of england 10 000 years ago well you know whatever time frame
00:43:43you were alluding to one thousand one thousand that's a more historically accurate but thank
00:49:39Exactly. They're anti-normative. That's a great way to say it. So all of that is to say,
00:49:42It seems to me that the entire field of psychiatry, or at least part of it, could be viewed as an anti-normative response to a modern world, at least when it comes to certain things like anxiety and depression.
00:49:54Yeah. And it's interesting, you bring up sleep. I think all the foundational biological factors,
00:50:02so in my model of endocrinology, certainly hormones and the endocrine system are part of it,
00:50:12but also inflammation, metabolism, and stress circuitry, in addition to circadian biology
00:50:21and sleep architecture, all those factors are challenged by modernity. If we want to look at
00:50:28metabolism, diets and people weren't needing to go on GLP-1s a thousand years ago, maybe unless
00:50:37they were the king. That's right. We know the king had gout, but we don't know if anybody else
00:50:42did. You raise a great point, and I've discussed this also on the podcast in the past, this mental
00:50:49model of distress tolerance. And I wrote about this actually in my book, which was,
00:50:54this is the model that I use. It's how I think about my life. So when I'm irritable, which let's
00:51:00be honest, I can be quite irritable. I'm imagining kind of a window in which I occupy. And the window
00:51:08is my distress tolerance window. When that window is wide open, I can tolerate a lot. I can take a
00:51:15lot of bullets and I'm fine. Yeah. When that window is narrow, even the littlest thing will0.87
00:51:21sort of irk me. If my kid does this or if my wife says this or an employee says this, I'll be
00:51:27irritable. Okay. So then I ask the question, what determines the width of my window? And what's
00:51:34amazing but obvious is what you just said. Your biology plays such a role in that window. Yeah.
00:51:42If I exercised or didn't exercise, that's an enormous contributor to the width of my window.
00:52:06And I didn't think anything of it, but as I found myself irritable two weeks into this,
00:52:11someone said, untreated pain is going to make you irritable. I could rattle off all the things
00:52:18that do it. But everybody, I think, has to kind of discover what creates, what lengthens their
00:52:23window. And do you get the impression- Yes and no. I mean, it's part of the human condition
00:52:28that we all have these foundational biological factors and we have an adaptive capacity.
00:52:36and that's always changing over time how much of that is part of psychiatry like you obviously you
00:52:42as a psychiatrist are attuned to that but do you do you get the impression that that should be part
00:52:46of the foundational treatment which is yes i know that you're depressed i know that your anxiety is
00:52:51this way or the other way i know that you're irritable but are we looking at your nutrition
00:52:55are we looking at how much you exercise are we trying to regulate your sleep and are we actually
00:52:59treating some of those underlying foundations as well well i think a lot of psychiatrists are
00:53:04And there are specialists, like for example, in nutrition and psychiatry, sleep and psychiatry, there's a lot of research being done on the pathophysiology of metabolism and its role in psychiatric illness.
00:53:24And I think most psychiatrists try hard to touch upon those things.
00:53:31So I'd be careful to say anybody wasn't doing it adequately to generalize.
00:53:40But I think we have to have a framework about how to think about it, that the brain doesn't operate in isolation.
00:53:50And it's part of this larger system with bidirectional feedback.
00:53:54And so when you have a toothache, that's obviously tapping into your stress circuitry, that's affecting your cortisol levels, that's affecting potentially if it's going on, that's affecting your memory because it's toxic to the hippocampus.
00:54:15You're producing less BDNF, which is critical for neuroplasticity.
00:54:22So on many different levels, there are these continuous bi-directional interactions between what happens on a neurotransmitter level and what happens with the foundational biological factors.
00:54:37I just chose endocrinology as the one I wanted to focus on because it fascinated me particularly.
00:54:45Well, that's great because that's exactly where I kind of wanted to go.
00:54:48let's go back in time five years ago when this interest of yours started. Why did you pick
00:54:55endocrinology and how did you dip your toe in that water? Yeah. Well, I was always interested
00:55:00in endocrinology and I have some friends, colleagues who are endocrinologists, but I was
00:55:06really struck by the impact of the interpretation and the reinterpretation of the Women's Health
00:55:14Initiative and how that changed prescribing practices so profoundly in general medicine,
00:55:21it led me to think, well, if that happened in general medicine, how is it affecting the
00:55:26appreciation of endocrinology in psychiatry? And I concluded that endocrinology, from my
00:55:36perspective tends to be, at least by me, previous to that, was significantly underappreciated in
00:55:46psychiatry. And that there are a number of reasons for that. But that was something I wanted to
00:55:54roll my sleeves up and get into. So I sort of went back to school, so to speak. I took
00:56:01a course in bioidentical hormone replacement therapy. I got certified as an advanced practitioner
00:56:08of BHRT, which just opened a window, and I did a number of other educational activities
00:56:15to learn more about it. And I found it to be fascinating, particularly how I feel the
00:56:25neural circuits and neurotransmitters are really inseparable from the endocrine system.
00:56:34So I want to go back to something you said. You've talked about the WHI.
00:56:37Your career has spanned pre and post-WHI. So 25 years ago, you got to witness the complete
00:56:45reduction in the prescription of estrogen for women during menopause. What was the impact you
00:56:53saw in your practice as you saw women go from receiving hormones at the time of menopause to
00:57:01women being deprived of hormones? Variable. Variable. And it was so long ago and I was so
00:57:13relatively ignorant as to where I am now that I'd be hesitant to make any generalizations about it.
00:57:21But you brought it up as, hey, five years ago, which means you're 20 years post-WHI. It was still kind of clearly there was still something there that made you think about it.0.76
00:57:31impact on me. I had the impression that people, again, getting back to adaptive capacity, that
00:57:38women whose adaptive capacities were higher, their ability to self-regulate and adjust to
00:57:44internal and external threats and changes was being eroded off of estradiol.
00:57:54And similarly, for both sexes, that men who needed testosterone weren't getting it,
00:58:04were being told it wasn't safe, similarly had an erosion of their function across multiple domains.
00:58:15So I don't think there's a way that we can dive into this, Linus,
00:58:19without you explaining some of the biology of how estradiol and testosterone and maybe even
00:58:25progesterone or levofibroxine, like all of these things. Yeah. Let's start with estradiol. I mean,
00:58:31I share your point of view. I feel very strongly that estradiol is one of the most important
00:58:38hormones in the brain, both for men and women. So maybe walk us through kind of some of the
00:58:47reasons why that's the case? Because it probably isn't intuitive to everybody.
00:58:51Definitely not. It wasn't to me. So in preparing for the podcast, I came up with a mouthful,
00:58:57but estradiol is a constitutive, pleiotropic, multi-system regulator of neurotransmitters
00:59:07and neural circuits. So constitutive, what does that mean? It means part of the architecture
00:59:15evolved. Hormones were evolved by the brain for the brain. So there's no separation of
00:59:22the endocrine system and the brain at that level. Pleotropic, it has multiple actions
00:59:30at multiple levels throughout neurotransmission. So for example, estradiol modulates not only
00:59:40serotonergic transmission profoundly, but also the dopamine system, the GABA system,
00:59:47acetylcholine, NMDA, and glutamate. So it's really profound. And it serves a regulatory
00:59:58function. While psychotropics are signal amplifiers, estradiol, for example,
01:00:07is a system modulator. It creates the conditions within which neurotransmission occurs.
01:00:19Do we know how these hormones are regulated in the brain? We have a pretty good sense of how
01:00:24they're regulated in the periphery. We understand the feedback loops. It's actually hard to
01:00:30disentangle them because, quite frankly, it's the pituitary gland that does so much of the
01:00:34regulation in the periphery through luteinizing hormone and follicle-simulating hormone.
01:00:40Well, it's the HPG axis, the hypothalamic-pituitary-gonadal axis,
01:00:46and all the bidirectional feedback that occurs within that framework.
01:00:54In other words, is there actual estradiol in a synapse, or is it removed from that given its
01:01:00size and it's regulating upstream of the actual synaptic contents between where the actual
01:01:08neurotransmitters live? No. There are receptors for it on the membranes of neurons. So they're
01:01:17well-characterized. There's membrane estrogen receptor alpha and membrane estrogen receptor
01:01:24beta. And there are also transcriptional binding sites, estrogen response elements within our
01:01:33genomes. So estrogen is penetrating to the deepest level of our central nervous system
01:01:40where transcription is regulated. And that, for example, is how serotonin synthesis is upgraded
01:01:50through tryptophan hydroxylase. There are specific estrogen response elements that bind to promoting
01:01:58factors for tryptophan hydroxylase, therefore increasing serotonin. The same thing for dopamine
01:02:06through tyrosine hydroxylase. The same thing for acetylcholine through choline acetyltransferase.
01:02:14So it's right there. It's at ground zero of neuronal activity, which is fascinating.
01:02:23And that's part of why I find the whole thing just so remarkable, that it's embedded within the brain.
01:02:32I had another term that I was searching for, imbued with and embedded within the brain is how I think about it.
01:02:41And so let's now talk about the removal of that. So everything you said kind of explains
01:02:50the biology of what estrogen is doing. But now let's characterize the phenotype.
01:02:55So if estrogen is reduced, all other things being equal, how does the brain experience that?
01:03:05Well, let's think of evolution. Estradiol evolved to be not only a sex hormone, but this pleiotropic regulator of other systems, because for successful reproduction, it's not only conception that's required, it's nurturing, it's forming social bonds, it's acquiring resources.
01:03:34So therefore, this pleiotropic role has been evolutionarily very adaptive, that one hormone has these multi-system effects.
01:03:48And that's why you see women with low estrogen having multiple domain challenges from cognition to mood regulation to anxiety to a number of other challenges.
01:04:05And why do you think it is so variable, Linus?
01:04:08I can't imagine you haven't seen what any doctor has seen in this situation, which is there are some women whose cognitive symptoms in the presence of estrogen withdrawal are incompatible with normal life, and there are other women who barely notice it.
01:13:53Yeah. So you don't have to go and see a doctor formally to do it. It can be kind of a jack-in-the-box
01:14:00online thing that can give it to you. But you're correct. The few times we have used it for
01:14:05patients who want to preserve fertility, want to rely on endogenous function, don't want to deal
01:14:11with needles, it really fixes the numbers. It just doesn't seem to fix the symptoms.
01:14:16Yeah. That seems to be the case. Not always. There are some people who take it and
01:14:22do well. But compared to exogenous testosterone, testosterone cypionate injection, for example,
01:14:32dramatically better responses. Yeah. Let's talk a little bit about progesterone.
01:14:38Sure. You've already alluded to it in one very important capacity, which is in the case of a
01:14:44woman who is experiencing a somewhat regular menstrual cycle, you already mentioned that
01:14:49in the second half of the luteal phase. And I guess it's worth... It's sometimes easier if
01:14:54people can picture how the hormones cycle during a woman's cycle. But progesterone is the easiest
01:15:00one, I think, to draw. Because for the first 14 days during the follicular phase, from the moment
01:15:06she has her period until she ovulates, there's nothing. It's flatline. And then it rises as it
01:15:12prepares for implantation. It hits a peak, assuming there is no implantation. And it's important to
01:15:18mention why that is. Because it comes from the corpus luteum, the follicle that is broken,
01:15:26and the lining of that follicle, I believe, is what secretes the progesterone.
01:15:32Right. In preparation for the follicle to be implanted. But once it's not implanted,
01:15:38the lining sheds, which is what the period is. But the point that you're making is,
01:15:43but it's that progesterone that is crashing down. And what I find very interesting is that
01:15:50the woman didn't feel bad when her progesterone level was low, right? Because she felt fine
01:15:58during the follicular phase. No oscillation. Exactly. It's the fall back to low from high
01:16:04that causes the symptoms. This is incredibly fascinating.
01:16:07It is. And one of the most fascinating paradigms in human biology is postpartum,
01:16:14where progesterone goes from all-time highs, and so does estradiol. Estradiol goes from
01:16:2130,000 to, let's say, 30. Progesterone goes from several hundred to less than one
01:16:30within 24 to 48 hours, it's amazing that women do as well as they do. I'm in awe of-
01:16:39In other words, yeah. I just want to make sure the listener knows what you're saying.
01:16:41The more I learn about hormones, the more in awe of women I am.
01:16:44Yeah. You're in awe that more women don't experience postpartum depression.0.52
01:16:48Yeah. But I'm in awe of all women for having to deal with these issues that
01:16:54guys don't have to deal with and how profound they are and how challenging they are.
01:17:00So do you think we understand why, and I know you've talked about it in terms of genetics,
01:17:08receptor density, is there anything else we know about why some women will experience that drop
01:17:13in progesterone over the course of a week and the last part of their cycle and be really debilitated
01:17:20by it, and while some will not notice it. How genetic is it? I assume there's a strong
01:17:26concordance between mother-daughter? I believe it's highly genetic, yes.
01:17:31Do you know how predictive that is of postpartum depression or how predictive that is of cognitive
01:17:38or depressive symptoms during menopause when there's a depletion of both progesterone and
01:17:45estrogen? I'm not sure. I'm not sure. There is a correlation. I'm not sure how high a correlation
01:17:51there is. But I would think there would be a very high prevalence of women who have severe
01:18:03postpartum depression or psychosis who also have PMDD, but not the converse.
01:18:10Yeah, let's talk about postpartum depression. Do you see any women for that in your practice?
01:18:17Yes, only because postpartum depression is a very heterogeneous condition.
01:18:24The most dramatic example of severe postpartum depression and psychosis happens within a week
01:18:32of childbirth. And it usually unfolds in a hospital where a woman goes from a normal
01:18:42frame of mind. And with estradiol levels and progesterone at their peaks, these women are,
01:18:49you know, women in general at the end of pregnancy are primed to be in wonderful moods.
01:18:55And they go from there to having the ones who are afflicted by severe cases of postpartum depression and psychosis start to become suspicious of the hospital personnel, become hypervigilant about where the baby is and have very intense separation anxiety,
01:19:17can have intrusive ideation about harming their own children themselves without wanting to,
01:19:26but having some fear. It's an OCD-like phenomenon that they can have a fear that they can
01:19:32do something that they would never do. And we don't know why this happens to some
01:19:37women. And fortunately, few women- It's being researched. Hopkins has a big program in that.1.00
01:19:43Do you know the prevalence of that severe a level of postpartum depression?
01:21:28What are you thinking about as you start to lay out treatment options?
01:21:33How much do you, and again, maybe I'll just make it a little straightforward and say,
01:21:38let's assume there are no other comorbid conditions that would make the, yeah.
01:21:42Pretty similar to non-postpartum depression.
01:21:47It's only the acute type where there's a synthetic analog of that chemical that the body makes, the hormone, allopregnanolone, called xeranolone, which is now in a pill form.
01:22:03It used to be brexanolone, which was an intravenous infusion given in an ambulatory center where a woman had to stay there for a protracted period of time.
01:22:17think about a woman who's having all these issues and has to be separated from her family and her
01:22:23baby, you know. So fortunately, they came out with an oral form of it. The generic name is0.99
01:22:29xeranolone. And it's a synthetic version of the neurosteroid allopregnanolone, which is the
01:22:38breakdown product of progesterone via five alpha reductase and three alpha hydroxy steroid
01:22:46hydrogenase. So would you give that as monotherapy or do you give that in combination with, for
01:22:53example, an SSRI? Oh, well, that's the one in the hospital that starts in the hospital.
01:22:58Okay. But when she's- When she goes home. When she goes home, what do you-
01:23:01No. All other things being equal, you just give that.
01:24:34So if they were well for 34 years, and then they have this one episode, I would say, oh,
01:24:44evidence-based medicine would suggest that you stay on this medication for somewhere
01:24:49on the order of 8 to 12 months. And then we could, depending on if you respond well,
01:24:57we could taper you off of it slowly and see how you do. But I wouldn't think at all that you have
01:25:05to be on this medication indefinitely. But if they said that they went into it and they had
01:25:12dysthymic tendencies that weren't diagnosed, like pessimism, constant irritability,
01:25:20just sadness, and they felt that their mood was beneath baseline for most of it, then I would say,
01:25:30well, let's see what you want. It isn't what you need. It's more a quality of life issue.
01:25:35Because often what happens in a situation like that is a woman goes on a medication for an acute depression and she finds her new baseline is better than her premorbid baseline.
01:25:50So she feels better than she did before she ever started taking the psychotropic or had the certainly better than before she had the major depression.
01:26:01So in other words, the pregnancy may have unmasked something that she was just sort of stoically pushing through before?
01:26:28I think it's kind of intuitive to people that, well, maybe it's not, actually. Maybe it's not.
01:26:36So let's just take it away with how does T3 and T4 and TSH interact with the psychiatric system
01:26:45overall? Sure. Well, just to give an overview of it, TSH is what the pituitary thinks of the
01:26:56thyroid axis. And what I find is that a lot of people with quote-unquote normal values of TSH,
01:27:07which is often what the average internist measures in the average psychiatrist, people with
01:27:19normal range TSH, let's say in the top 50% of that range. So if the normal range is 0.8 to 5.0,
01:27:32people, let's say in the range of 2.5 to 5, are often considered normal and dismissed.
01:27:40But that's often indicative of a real foundational deficiency in thyroid hormone, because that's only a signal to the thyroid to produce thyroid hormone.
01:27:56In thyroid hormone, there are two types. T4, which has two functions. It's a prodrug and it
01:28:05gets into the central nervous system to be converted centrally there to T3. And it's also
01:28:14a prodrug in the periphery. So there are two different types of diaginases, enzymes that
01:28:22convert them. So free T4 is a very, very important value. And if free T4 is suboptimal in a patient
01:28:34with depression, it's a signal to me that that person should have an endocrine consult or I
01:28:42myself should directly prescribe them thyroid supplementation. So do you rely more on the
01:28:49TSH level or the free T4 level? Yeah, free T4 and free T3. Yeah, but primarily free T4.
01:28:59And if the TSH level is in the middle or low end of the range, but the free T4 is low,
01:29:10how do you act versus if the TSH is in the higher end of the range, but the free T4
01:29:18is also in the higher end of the range? How do you act in those two settings?
01:29:22Well, I'm not concerned about the TSH. I'm concerned about the free T4.
01:29:29So that's the biomarker that's more of interest.
01:47:08And she had gone to a previous psychiatrist for a, I would call it a bipolar depression, an episode of depression that happened in her 30s after she had a extended hypomanic period of incredible productivity.
01:47:27She crashed and could barely get out of bed and went to the psychiatrist.
01:50:20So what it does is it results in this massive release of glutamate and the excitatory response as well as the mTOR pathway and protein synthesis and synaptic remodeling.
01:50:42So it happens remarkably fast, and it stops remarkably fast.
01:50:48So what's incredible about it is you can have a patient who's on the edge of being committable, requiring hospitalization because they can't contain their suicidal feelings, and you can send them for a ketamine infusion, and the suicidal risk dissipates dramatically, dramatically better.
01:51:11the depression doesn't necessarily. So basically, in my experience, I've used it sort of as a bridge
01:51:20to finding the solution for that patient, rather than it being the solution. Occasionally,
01:51:26it is the solution. And the patient goes for ketamine treatments and goes into remission
01:51:32from their depression. But more often than not, in my experience, they don't. And you have to
01:51:40find the right drug or the right other approach to definitively treat their depression on a longer
01:51:48time basis. Do patients become resistant to the effect over time? Is there a
01:51:57tachyphylaxis that develops? Yeah. I'm not that expert in ketamine, honestly,
01:52:03so I'm not sure. I haven't seen that. Because practically, it's very time-consuming,
01:52:12expensive, and inconvenient. The patients that you would send for this treatment,
01:52:18how is it administered? Is it administered intravenously?
01:58:02So this N of 1 study is something I can't draw any conclusion from, but I find it theoretically
01:58:11interesting that so much adaptive capacity could be restored. So if PTSD was the etiology and she
01:58:21would regress and this interfered and turned around the regression, that's wonderful. Whatever
01:58:29it is, if it helped this patient, it's a wonderful initial response. I'd be very cautious about
01:58:37generalizing that neurodegenerative disease. You know, the Robin Carhart-Harris rebus model,
01:58:46relaxed belief under psychedelics, is about neuroplasticity for adjusting maladaptive
01:58:53priors, people who have beliefs that are problematic for them and the underpinnings
01:59:01of a lot of depressive and anxiety disorders. And administering classic psychedelics
01:59:10provides a therapeutic window within which a lot of neuroplasticity occurs and with the right
01:59:19response either within the individual or between the individual and family or formal therapists,
01:59:29change can occur in that critical window. And I find that of interest because, of course,
01:59:38estradiol creates a lot of neuroplasticity because it acts through BDNF and NMD and glutamate.
01:59:48And so the hormones that change the conditions within which neurotransmitters operate are very plastic under the right circumstances, optimal estradiol levels, for example.
02:00:09And administering a psychedelic medication can also alter neuroplasticity, is intended really, to alter neuroplasticity in the studies of psychedelics for the most part.
02:00:25Not all, but a lot of them are thinking of that set and setting model, which is based on a concept of neuroplasticity.
02:00:33Now, what's your experience been of psychedelics?
02:00:40I have tried in as clinical a setting as I think possible several of these psychedelic agents.
02:00:50So I have tried ketamine under therapeutic conditions once.
02:00:57I didn't find it to be a positive experience and I will never repeat it.
02:01:01do you want to elaborate about the negative aspects of it um i you know i described it to
02:01:10a friend after as guantanamo bay for my soul and my psyche i mean absolutely devastating
02:01:18so just a endless spiral of death did anything positive come out of that subsequently not a
02:01:28single positive thing came out of that. So you had a profoundly adverse reaction?
02:01:33Perhaps the only positive thing I would say is it gives me enormous caution when I talk to my
02:01:39patients who themselves are very curious about these things. I just caution them and say, look,
02:01:46you simply don't know how you're going to respond to these things. The therapeutic
02:01:51windows on these things are quite narrow. And they're just not well understood. It's not like,
02:01:57hey, if we're going to give you Prozac, we sort of know that most people respond at this dose.
02:02:05Some people need it to be at this dose. Some people need it to be at this dose. These are
02:02:09the side effects. If this happens, we're going to- You're on to my Russian roulette concept.
02:02:13Yeah. Yeah. So I think with these agents, I mean, with the exception of MDMA, I think all of these
02:02:19these so-called psychedelics, I think are, and again, there are, you know, I've used psilocybin
02:02:27in a therapeutic setting that was incredibly positive. I've also had, but I've had experiences
02:02:35on psilocybin that were brutal. I mean, I had one experience on psilocybin where I, you know,
02:02:42it's hard to know exactly how much time was was was passing but but certainly for hours it it um i
02:02:50had a reoccurring experience of being in a guillotine where the blade was dropping and so
02:02:56what i was experiencing was the sound of the blade as it's getting closer to the back of my neck but
02:03:01it would always stop just before it hit my neck so that would provide a modicum of relief but then
02:03:07the blade would go back up and it would happen again wow so that was absolutely awful again
02:03:12nothing positive came of that experience but i've had i've had very positive experiences
02:03:17on guided mdma and and with uh with with with another psilocybin experience um and i think
02:03:24what made the positive experience positive um well again i think with mdma no with the psilocybin
02:03:34Um, it was, I mean, it's hard to describe. I think it's, it's, this is over 10 years. This
02:03:40is about 10 years ago. It was an out of body experience, meaning I was only witnessing myself
02:03:47from outside of myself, but at different places in my life. But they were very vivid. These were
02:03:55not vague images. This was, you are back in this room at this moment in your life when you were 12
02:04:05years old. And this is exactly what's happening. But what was very powerful about this was I was
02:04:15not experiencing it through my lived experience, but through the other person in the room,
02:04:22in this case a parent and for me that gave incredible empathy to what was going on with
02:04:32the other person during an experience in my life yes so that and the durability of that is
02:04:40a decade later that that will be lifelong durability so i think because that's a fascinating
02:04:47description beautifully expressed about something fundamental about people
02:04:57maybe in a different category who revisit a traumatic experience from a more developed
02:05:04perspective in their lives and they're able to re-assimilate it from certainly a more advanced
02:05:14view and even have compassion for someone who may have. So this was an interesting experience.
02:05:20This was not a traumatic experience in my life at all. And so therefore it's very unclear to me
02:05:26in this particular instance, why I went to that place, but instead what it gave me was,
02:05:37and it might've been that I was at the exact same age as my parent at the, in other words,
02:05:43in my life, I was the same age as my parent in this vision. But now all of a sudden I was able
02:05:49to appreciate their life and how much harder it was than my life. But in a way that I could never
02:05:58articulate now, I can't describe it now. It was the feeling of, wow, their life was so much harder
02:06:06than my life. And everything I have is because of them and their sacrifice. And all of the things
02:06:16that have frustrated me are frustrations of someone who's never fully appreciated.
02:06:26Yes. So it was, I think, one of the most beautiful experiences I've ever had in my life.
02:06:31And what's interesting is it was the first experience. And therefore, when you have such a positive first experience, what do you want to do? You want to go back to that well every few years. Because if it was that transformative in this one regard, imagine what it could do for other relationships in my life. And unfortunately, it has never come close to reproducing that. It has been anywhere from neutral to negative.
02:06:57And so I made a decision about two years ago that I was probably never going to do that again.
02:07:04I was sort of, and I won't describe the litany of things I've tried, but I will never, I just don't.
02:10:30Yeah. Well, I mean, it might just be that my horror stories have to do more with where I am
02:10:39on the dose response group. It's interesting. I had a discussion yesterday with a patient about
02:10:43estradiol. He had been under the care of a doctor before he came into our practice that was trying
02:10:48to give him a Remedex, which for the listener is a drug that prevents the aromatization of
02:10:53testosterone into estradiol. And he had been taught, so to speak, that estrogen was bad and
02:10:59you want high testosterone and low estrogen. So needless to say, we had a great discussion about
02:11:03why that was a very bad idea. Yeah. What hope do you hold out for the utilization,
02:11:14the proper utilization of psychedelics in psychiatric medicine over the next 10 to 20
02:11:19years? Well, part of it relates to your positive experience. It's extraordinary that a single
02:11:26administration of a drug can produce a durable effect that you're projecting will last a lifetime.
02:11:34I'm 100% convinced it will last the rest of my life.
02:11:36And I'm 100% convinced by you of the power of that experience and how transformative it is.
02:11:45So I find it remarkably exciting and promising, but I also appreciate the dangers and unpredictability.
02:11:55So I'm hoping that they'll find a strategy, they meaning the researchers in that field, will find either a molecule that preserves the risk-benefit ratio shifting much more favorably or a set-in-setting strategy that modifies or some other strategy, maybe combination pharmacotherapy.
02:12:24pharmacotherapy, because it is a pharmacotherapy. It's the use of a psychotropic medication. Maybe
02:12:29concurrent use of other medications that don't block the serotonin 2A receptor that it has to
02:12:37bind to. That's where the classic psychedelic binds to. So if you block that receptor with
02:12:43another drug, instead of needing twice as much, you may need 20 times as much. So that's not
02:12:49reasonable, but finding an appropriate pharmacologic strategy that augments the efficacy and mitigates
02:13:01the risk. Of all of the indications that are being talked about for these drugs, the two that,
02:13:07to me, seem the most exciting are obviously MDMA and PTSD and psilocybin in end-of-life
02:13:17depression or frankly, just all end of life related therapy. What do you think, how much
02:13:26more evidence do you think the medical community, I mean, the FDA aside, there's a whole issue with
02:13:32the FDA there, but from a medical scientific standpoint, where do you sit on those two
02:13:38indications, which are quite specific? Yeah. Well, end of life treatment, the risk reward
02:13:44shifts a little bit. If someone is struggling with existential anxiety on an absolute order,
02:13:54I think if there's something that could help them with that, they deserve the option of exercising
02:14:02that. Because there aren't many things- But we don't want to make it worse.
02:14:06We don't want to, but it's pretty bad to begin with. So the risk-reward may shift. It depends
02:14:15on your medical ethical model. If the baseline would shift the risk-reward calculus about that,
02:14:23I'm not sure. Something worth thinking about. But then the same would apply to significant PTSD.
02:14:30Yeah, but I suspect that it's not MDMA that's going to be the most effective for that.